| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (frommouse) |
| Target | CD40 ligand |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
 N Y (what is this?) (verify) | |
Toralizumab (IDEC 131) was ahumanized monoclonal antibody and animmunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura,lupus nephritis,rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis,Crohn's disease, andtransplantations such as solid organ transplantation, pancreaticislet cell transplantation, andcorneal transplantation), and B-cell malignancies such asCLL/small lymphocytic lymphoma,follicular cell lymphoma grade I or II,marginal zone lymphoma,mantle cell lymphoma,MALT lymphoma,Waldenström's macroglobulinemia, monocytoidB-cell lymphoma; relapsed/refractoryHodgkin's disease).[1]
In Phase IIclinical trials regarding multiple sclerosis and Crohn's disease,thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted.[2]
The drug was developed byIDEC Pharmaceuticals Corporation.
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
